Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04789382 · ClinicalTrials.gov registry record · NA

Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations

A NA study of Refractive Errors, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT04789382: Completed NA study of Refractive Errors, sponsored by Alcon Research.

NCT04789382 is a NA study of Refractive Errors that has completed, run by Alcon Research. The registered enrollment target is 36 participants, below the 104-participant average among 14 other Refractive Errors trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04789382, a NA study of Refractive Errors, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate corneal staining observed after 2 hours of wear with an investigational contact lens against both PureVision contact lenses pre-cycled with Biotrue and Biofinity contact lenses pre-cycled with RepleniSH.

Primary Outcome

A slit lamp examination was performed by the investigator to assess corneal staining. Percent of solution-related corneal staining area was assessed first in each of the 5 corneal regions: central, superior, nasal, inferior, and temporal. The average of corneal staining area was then calculated as the average over all 5 regions. Each eye was treated differently and was graded separately. No hypotheses were formulated; no inferences were made, and only descriptive statistics were used in the repo

Conditions Studied

Interventions

  • DEVICE LID018869+RepleniSH
  • DEVICE LID018869+Biotrue
  • DEVICE Biofinity+RepleniSH
  • DEVICE PV+Biotrue

Study Locations (1)

Florida

  • Alcon Investigator 6565 - Maitland

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2021-04-07
Est. Completion 2021-05-07
Phase NA
Alcon Research

275 total trials

What the finished NCT04789382 record still lists

NCT04789382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 104-participant average among 14 other Refractive Errors trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Refractive Errors appearing as the primary indexed condition, and to 4 interventions - of which LID018869+RepleniSH is the first listed.

NCT04789382 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04789382 about?

NCT04789382 is a clinical study titled "Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations". The purpose of this study is to evaluate corneal staining observed after 2 hours of wear with an investigational contact lens against both PureVision contact lenses pre-cycled with Biotrue and Biofinity contact lenses pre-cycled with RepleniSH.

What is the current status of trial NCT04789382?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2021-04-07. Estimated completion is 2021-05-07.

What conditions does trial NCT04789382 study?

This clinical trial studies the following conditions: Refractive Errors.

What interventions are being tested in trial NCT04789382?

The interventions under investigation include: LID018869+RepleniSH (DEVICE), LID018869+Biotrue (DEVICE), Biofinity+RepleniSH (DEVICE), PV+Biotrue (DEVICE).

Who is sponsoring clinical trial NCT04789382?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04789382 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Refractive Errors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04789382's enrollment target sits among peer trials

36 11th of 14 higher than 4 of 14 other Refractive Errors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractive Errors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04789382, the US trial registry maintained by the National Library of Medicine. NCT04789382 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.